Mineralys Therapeutics, Inc. MLYS
Set alert
As of Nov 2, 11:18 AM ET
- YTD
- -55.79%
- 1 year
- -60.73%
- Open
- 18.27
- Prev close
- 18.18
- Mkt cap
- 1.41B
- Vol
- 1.26M
- Avg vol
- 1.28M
- EPS
- -4.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.70
- High
- 18.29
- Forward P/E
- -7.40
- Beta
- 0.69
- Short ratio
- 4.98
- Inst. own
- 117.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 24.93
- 200-d avg
- 27.07
- 1y target
- 46.33
News
4 days ago globenewswire.com
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
-
5 days ago benzinga.com
Mineralys Therapeutics Announces Phase 2 Explore-CKD Trial Met Its Primary Endpoint; Publishes Full Results In The Journal 'Kidney International'
The Explore-CKD trial evaluated the efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, added to guideline-directed background therapy in 59 participants with uncontrolled…
5 days ago globenewswire.com
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -
1 week ago globenewswire.com
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3…
1 week ago globenewswire.com
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
RADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
-
3 weeks ago benzinga.com
UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29
UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Neutral rating and announces Price Target of $29.
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $56 price target.
-
3 weeks ago benzinga.com
Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related outcomes in comorbid conditions such as chronic…
3 weeks ago globenewswire.com
Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood…
4 weeks ago defenseworld.net
Mineralys (NASDAQ: MLYS) CEO sells 75,000 shares under prearranged plan
What happened Mineralys Therapeutics, Inc. (NASDAQ: MLYS) said Chief Executive Officer and director Jon Congleton sold 75,000 shares on 2026-09-30. The Form 4 says the shares changed hands at a…
1 month ago globenewswire.com
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
-
1 month ago benzinga.com
Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientific Sessions 2026,
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as…
1 month ago globenewswire.com
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
1 month ago globenewswire.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
1 month ago defenseworld.net
Mineralys Therapeutics (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 104,320 Shares of Company Stock
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Brian Slingsby sold 104,320 shares of the business's stock in a transaction dated Tuesday, September 22nd. The shares were sold…
1 month ago globenewswire.com
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
-
1 month ago benzinga.com
Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN Open-Label Extension Trial Of Aldosterone Synthase Inhibitor Lorundrostat At AHA Scientific Sessions 2026
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as…
1 month ago globenewswire.com
Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
1 month ago defenseworld.net
Mineralys Therapeutics (NASDAQ:MLYS) Insider Eric Warren Sells 7,438 Shares
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider Eric Warren sold 7,438 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price…
1 month ago globenewswire.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
1 month ago defenseworld.net
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells $85,740.00 in Stock
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Daphne Karydas sold 3,000 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average…
1 month ago globenewswire.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related…
1 month ago defenseworld.net
Greenland Capital Management LP Sells 53,500 Shares of Mineralys Therapeutics, Inc. $MLYS
Greenland Capital Management LP reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ: MLYS) by 64.1% in the second quarter, according to its most recent filing with the Securities and…
1 month ago seekingalpha.com
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision
Mineralys Therapeutics, Inc. is upgraded to Buy, with lorundrostat poised for FDA approval in December and a strong commercial launch anticipated. Despite AstraZeneca's first-mover advantage with…
2 months ago defenseworld.net
Canada Pension Plan Investment Board Buys New Holdings in Mineralys Therapeutics, Inc. $MLYS
Canada Pension Plan Investment Board bought a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) in the undefined quarter, according to its most recent filing with the Securities…
2 months ago defenseworld.net
BlackRock Inc. Buys New Position in Mineralys Therapeutics, Inc. $MLYS
BlackRock Inc. purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) during the undefined quarter, according to its most recent Form 13F filing with the Securities and…
4 months ago benzinga.com
7 Health Care Stocks With Whale Alerts In Today's Session
7 Health Care Stocks With Whale Alerts In Today's Session
-
4 months ago benzinga.com
Reported Sunday, Mineralys Therapeutics Presents Late-Breaking Data At ENDO 2026 Showing Lorundrostat Associated With Significant Reductions In Six Of Eleven Heart Failure Risk Biomarkers
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –– Coordinated reductions…
-
4 months ago benzinga.com
Mineralys to Present New Trial Data at ENDO 2026, Proteomic Analysis Selected for Late-Breaking ENDO Poster
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD),…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
5 months ago benzinga.com
Mineralys Prices $150M Stock Offering Of 5.66M Shares At $26.50/Share, To Use Share Sale Proceeds for Royalty Buyback
Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD),…
5 months ago benzinga.com
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios
AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breast cancer treatment.
-
5 months ago benzinga.com
Mineralys Therapeutics Q1 EPS $(0.47), Inline
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 40.51 percent increase over losses of $(0.79) per share from…
-
7 months ago benzinga.com
B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51
B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.
-
7 months ago benzinga.com
Mineralys Therapeutics Q4 EPS $(0.40) Beats $(0.58) Estimate
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.58) by 30.68 percent. This is a 59.18 percent increase over losses…
-
7 months ago benzinga.com
Earnings Scheduled For March 12, 2026
Earnings Scheduled For March 12, 2026
-
7 months ago benzinga.com
Mineralys Therapeutics Says FDA Accepts NDA For Lorundrostat For Treatment Of Adult Patients With Hypertension In Combination With Other Antihypertensive Drugs; PDUFA Target Action Date December 22
– The FDA assigned a PDUFA target action date of December 22, 2026 –– The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction…
-
10 months ago benzinga.com
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.
-
10 months ago benzinga.com
Mineralys Therapeutics' Phase 3 Launch-HTN Trial Of Lorundrostat Featured In JAMA's Inaugural "Research Of The Year Roundup"
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most…
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56
HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $52 to $56.
-
11 months ago benzinga.com
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55
Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $50 to $55.
-
11 months ago benzinga.com
Mineralys Therapeutics Q3 EPS $(0.52) Beats $(0.65) Estimate
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.65) by 19.38 percent. This is a 53.98 percent increase over losses…
11 months ago benzinga.com
Earnings Scheduled For November 10, 2025
Earnings Scheduled For November 10, 2025
-
11 months ago benzinga.com
Reported Friday, Mineralys Therapeutics Showcases Broad Clinical Potential of Lorundrostat Across Cardio-Renal-Metabolic Diseases
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –– Pivotal Phase 3 Launch-HTN trial featured in the "Best of JAMA and NEJM" session -
-
12 months ago benzinga.com
Uncovering Potential: Mineralys Therapeutics's Earnings Preview
Uncovering Potential: Mineralys Therapeutics's Earnings Preview
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $42 to $52.
-
1 year ago benzinga.com
Mineralys Therapeutics Presents Phase 2 Explore-CKD Trial Of Lorundrostat At ASN Kidney Week 2025
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN…
-
1 year ago benzinga.com
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $50
Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $26 to $50.
-
1 year ago benzinga.com
Goldman Sachs Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $32 to $52.